Substituted piperazinyl amides and methods of use

A compound of Formula II

• wherein R10 is selected from H, chloro or fluoro;
• wherein R12 is
• wherein R13a and R13b are independently selected from H, phenyl, fluoro, iodo, bromo, chloro, phenyl, C1-2-alkyl, C1-2-haloalkyl, and C1-2-alkoxy;
• or wherein R13a and R13b together form an C1-4-alkenylenyl bridge;
• wherein R14 is selected from R19R20N—, R19R20N—C1-4-alkyl, (R21R22N—) (O=)C-, C1-4-haloalkyl, C2-4-hydroxyalkyl, heterocyclyloxy-C1-4-alkyl, aryloxy-C1-4-alkyl and C1-4-alkoxycarbonyl;
• wherein R15 is selected from H, C1-2-haloalkyl, C1-4-alkyl, halo, —OR17, and —N(R17)2;
• wherein R16 is selected from 3-pyridyl, 4-pyridyl, 5-benzopyrrolyl, 2-benzofuran, 2-benzothienyl, 6-quinolyl, thienyl, 4-piperidyl, N-methyl-4-piperidyl, N-methyl-2-piperidyl, N-ethyl-4-piperidyl, N-isobutyl-4-piperidyl, 3-piperidyl and 3-azetidinyl optionally N-substituted with a substituent selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, cyclohexylmethyl and benzyl;
• wherein R17 is selected from H, C1-4-alkyl, C3-7-cyclhoalkyl-(CH2)n—, and aryl-(CH2)n—;
• wherein R19 is selected from H, R23SO2—, C1-6-alkyl, C3-7-cycloalkyl-(CH2)n—, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, C3-7-cycloalkylamino-C1-6-alkyl, C3-7-cycloalkyl-C1-6-alkylamino-C1-6-alkyl, heteroarylamino-C1-6-alkyl, heteroaryl-C1-6-alkylamino-C1-6-alkyl, arylamino-C1-6-alkyl, aryl-C1-6-alkylamino-C1-6-alkyl, heteroaryloxy-C1-6-alkyl, heteroaryl-C1-6-alkyloxy-C1-6-alkyl, aryloxy-C1-6-alkyl, aryl-C1-6-alkyloxy-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkylthio-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, C1-6-alkylcarbonyl, C1-6-alkoxycarbonyl, C1-6-alkoxy-C1-6-alkylcarbonyl, C1-6-alkylaminocarbonyl, arylcarbonyl, aralkylcarbonyl, C3-7-cycloalkylcarbonyl, C3-7-cycloalkyl-C1-6-alkylcarbonyl, heteroaryl-C1-6-alkylcarbonyl and heteroarylcarbonyl;
• wherein R20 is selected from H, C1-8-alkyl, C3-7-cycloalkyl-(CH2)n—, C1-3-alkylsulfonyl, amino-C1-3-alkylamino, heterocyclyl-(CH2)n—, and aryl-(CH2)n—;
• alternatively R19 and R20 together with the nitrogen atom form a 4-8 membered heterocyclic ring;
• wherein R21 is selected from H, C1-6-alkyl, C2-6-alkenyl, C1-6-alkylthio-C1-6-alkyl, C1-6-alkylcarbonylamino-C1-6-alkyl, amino-C1-6-alkyl, heterocyclyl-(CH2)n—, C3-7-cycloalkyl-(CH2)n—, and aryl-(CH2)n—;
• wherein R22 is selected from H, C1-6-alkyl, C3-7-cycloalkyl-(CH2)n—, heterocyclyl-(CH2)n— and aryl-(CH2)n—;
• alternatively R21 and R22 together with the amide nitrogen atom form a 4-7 membered saturated heterocyclic ring;
• wherein R23 is selected from H, C1-6-alkyl, C3-7-cycloalkyl-(CH2)n—, heterocyclyl-(CH2)n— and aryl-(CH2)n—;
• wherein n is 0, 1, 2 or 3;
• and
• wherein m is 0, 1 or 2;
• wherein aryl, heterocyclyl are optionally substituted with one or more substituents selected from C1-2-haloalkyl, C1-3-alkyl, C3-6-cycloalkyl-(CH2)n—, chloro, fluoro, —OR17, —NR17CO2R17, —NR17SO2R17, N(R17)2, cyano, —COR17, —C(R17)2N(R17)2, nitro, —SO2N(R17)2, —S(O)mR17, and C1-3-haloalkoxy;
• and a pharmaceutically-acceptable salt thereof.